TEST BANK |
Test Bank For Focus on Nursing Pharmacology
| | | | | |
| 7th Edition by Amy M. Karch
| | | | |
TEST BANK |
, Test |Bank |For |Focus |on |Nursing |Pharmacology |7th |Edition |by |Amy |M. |Karch |Table
|of |Contents
Chapter |01- |Introduction |to |Drugs
|Chapter |02- |Drugs |and |the |Body
|Chapter |03- |Toxic |Effects |of |Drugs
Chapter |04- |The |Nursing |Process |in |Drug |Therapy |and |Patient |Safety
|Chapter |05- |Dosage |Calculations
Chapter |06- |Challenges |to |Effective |Drug |Therapy
|Chapter |07- |Introduction |to |Cell |Physiology
|Chapter |08- |Anti-infective |Agents
Chapter |09- |Antibiotics
|Chapter |10- |Antiviral |Agents
|Chapter |11- |Antifungal |Agents
Chapter |12- |Antiprotozoal |Agents
|Chapter |13- |Anthelmintic |Agents
|Chapter |14- |Antineoplastic |Agents
Chapter |15- |Introduction |to |the |Immune |Response |and |Inflammation
|Chapter |16- |Anti-inflammatory, |Antiarthritis, |and |Related |Agents
|Chapter |17- |Immune |Modulators
Chapter |18- |Vaccines |and |Sera
Chapter |19- |Introduction |to |Nerves |and |the |Nervous |System
|Chapter |20- |Anxiolytic |and |Hypnotic |Agents
Chapter |21- |Antidepressant |Agents
|Chapter |22- |Psychotherapeutic |Agents
|Chapter |23- |Antiseizure |Agents
|Chapter |24- |Antiparkinsonism |Agents
|Chapter |25- |Muscle |Relaxants
Chapter |26- |Narcotics, |Narcotic |Antagonists, |and |Antimigraine |Agents
|Chapter |27- |General |and |Local |Anesthetic |Agents
Chapter |28- |Neuromuscular |Junction |Blocking |Agents
|Chapter |29- |Introduction |to |the |Autonomic |Nervous |System
|Chapter |30- |Adrenergic |Agonists
Chapter |31- |Adrenergic |Antagonists
|Chapter |32- |Cholinergic |Agonists
|Chapter |33- |Anticholinergic |Agents
Chapter |34- |Introduction |to |the |Endocrine |System
|Chapter |35- |Hypothalamic |and |Pituitary |Agents
|Chapter |36- |Adrenocortical |Agents
Chapter |37- |Thyroid |and |Parathyroid |Agents
| Chapter |38- |Agents |to |Control |Blood |Glucose |Levels
|Chapter |39- |Introduction |to |the |Reproductive |System
Chapter |40- |Drugs |Affecting |the |Female |Reproductive |System
|Chapter |41- |Drugs |Affecting |the |Male |Reproductive |System
|Chapter |42- |Introduction |to |the |Cardiovascular |System
|Chapter |43- |Drugs |Affecting |Blood |Pressure
Chapter |44- |Agents |for |Treating |Heart |Failure
|Chapter |45- |Antiarrhythmic |Agents
Chapter |46- |Antianginal |Agents
|Chapter |47- |Lipid-Lowering |Agents
Chapter |48- |Drugs |Affecting |Blood |Coagulation
|Chapter |49- |Drugs |Used |to |Treat |Anemias
|Chapter |50- |Introduction |to |the |Renal |System
|Chapter |51- |Diuretic |Agents
Chapter |52- |Drugs |Affecting |the |Urinary |Tract |and |the |Bladder
|Chapter |53- |Introduction |to |the |Respiratory |System
Chapter |54- |Drugs |Acting |on |the |Upper |Respiratory |Tract
|Chapter |55- |Drugs |Acting |on |the |Lower |Respiratory |Tract
|Chapter |56- |Introduction |to |the |Gastrointestinal |System
|Chapter |57- |Drugs |Affecting |Gastrointestinal |Secretions
|Chapter |58- |Drugs |Affecting |Gastrointestinal |Motility
|Chapter |59- |Antiemetic |Agents
, Chapter |1: |Introduction |to |Drugs
Cognitive |Level: | Application
|Difficulty: | Moderate
Integrated |Process: | Nursing |process
1.A |nurse |working |in |radiology |administers |iodine |to |a |patient |who |is |having |a
|computerized |axial |tomography |(CAT) |scan. |A |nurse |working |on |an |oncology |unit
|administers |chemotherapy |to |patients |who |have |cancer. |At |the |Public |Health
|Department, |a |nurse |administers |a |measles-mumps-rubella |(MMR) |vaccine |to |a |14-
|month-old |child |as |a |routine |immunization. |Which |branch |of |pharmacology |best
|describes |the |actions |of |all |three |nurses?
A) Pharmacoeconomics
B) Pharmacotherapeutics
C) Pharmacodynamics
D) Pharmacokinetics
Ans: B
Response:
Pharmacology |is |the |study |of |the |biologic |effects |of |chemicals. |Nurses |are |involved
|with |clinical |pharmacology |or |pharmacotherapeutics, |which |is |a |branch |of
|pharmacology |that |deals |with |the |uses |of |drugs |to |treat, |prevent, |and |diagnose |disease.
|The |nurse |working |in |radiology |is |administering |a |drug |to |help |diagnose |a |disease. |The
|nurse |working |on |an |oncology |unit |is |administering |a |drug |to |help |treat |a |disease.
|Pharmacoeconomics |includes |any |costs |involved |in |drug |therapy.
Pharmacodynamics |involves |how |a |drug |affects |the |body, |and |pharmacokinetics |is
|how |the |body |acts |on |the |drug.
Cognitive |Level: |Comprehension
|Difficulty: |Easy
Integrated |Process: | Nursing |process
2.A |physician |has |ordered |intramuscular |injections |of |morphine, |a |narcotic, |every |4
|hours |as |needed |for |pain |for |a |motor |vehicle |accident |victim. |The |nurse |is |aware |that
|there |is |a |high |abuse |potential |for |this |drug; |therefore, |morphine |is |categorized |as |a:
A) Schedule |I |drug
B) Schedule |II |drug
C) Schedule |III |drug
D) Schedule |IV |drug
Ans: B
Response:
Narcotics |such |as |morphine |are |considered |schedule |II |drugs |because |of |the |high |abuse
|potential |with |severe |dependence |liability. |Schedule |I |drugs |have |high |abuse |potential
|and |no |accepted |medical |use. |Schedule |III |drugs |have |a |lesser |abuse |potential |than
|schedule |II |drugs |and |an |accepted |medical |use. |Schedule |IV |drugs |have |low |abuse
|potential |and |limited |dependence |liability.
Cognitive |Level: |Comprehension
|Difficulty: |Easy
Integrated |Process: | Communication |and |documentation
3.A |nurse |working |for |a |drug |company |is |involved |in |phase |III |drug |evaluation |studies.
|Which |of |the |following |might |the |nurse |be |responsible |for |during |this |stage |of |drug
|development?
, Chapter |1: |Introduction |to |Drugs
A) Working |with |animals |who |are |given |experimental |drugs
B) Monitoring |drug |effects |in |patients |who |are |selected |to |participate |in |a |study,
|who |have |the |disease |that |the |drug |is |meant |to |treat
C) Collecting |records |of |symptoms |that |participants |experience |while |taking |a
|drug |and |determining |whether |they |are |caused |by |the |disease |or |the |drug
D) Informing |healthy, |young |volunteer |participants |of |possible |risks |that |could
|occur |from |taking |an |experimental |drug
Ans: C
Response:
Phase |III |studies |involve |use |of |a |drug |in |a |vast |clinical |market |where |patients |are |asked
|to |record |any |symptoms |they |experience |while |taking |the |drugs. |Nurses |may |be
|responsible |for |helping |collect |and |analyze |the |information |to |be |shared |with |the | Food
|and |Drug |Administration |(FDA). |Use |of |animals |in |drug |testing |is |done |in |the
|preclinical |trials. |A |select |group |of |patients |who |are |involved |in |phase |II |studies
|participate |in |studies |where |the |participants |have |the |disease |the |drug |is |intended |to
|treat. |These |patients |are |monitored |closely |for |drug |effects. |Phase |I |studies |involve
|healthy |human |volunteers |who |are |usually |paid |for |their |participation. |Nurses |may
|observe |for |adverse |effects |and |toxicity.
Cognitive |Level: |Comprehension
|Difficulty: | Moderate
Integrated |Process: | Nursing |Process
4. Which |of |the |following |concepts |is |considered |when |generic |drugs |are |substituted |for
|brand-name |drugs?
A) Bioavailability
B) Critical |concentration
C) Distribution
D) Half-life
Ans: A
Response:
Bioavailability |is |the |portion |of |a |dose |of |a |drug |that |reaches |the |systemic |circulation
|and |is |available |to |act |on |body |cells. |Binders |used |in |a |generic |drug |may |not |be |the
|same |as |those |used |in |the |brand-name |drug. |Therefore, |the |way |the |body |breaks |down
|and |uses |the |drug |may |differ, |which |may |eliminate |a |substitution. |Critical
|concentration |is |the |amount |of |a |drug |that |is |needed |to |cause |a |therapeutic |effect.
Distribution |is |the |phase |of |pharmacokinetics |that |involves |the |movement |of |a |drug |to
|the |body's |tissues. |A |drug's |half-life |is |the |time |it |takes |for |the |amount |of |drug |to
|decrease |to |one-half |of |the |peak |level.
Cognitive |Level: | Analysis
|Difficulty: | Difficult
Integrated |Process: | Teaching/learning
5. A |nurse |is |teaching |her |patient |about |the |use |of |over-the-counter |(OTC) |drugs. |Which |of
|the |following |statements |best |informs |the |patient |about |their |safe |use?
A) “OTC |drugs |are |products |that |are |available |without |prescription |for |self-
|treatment |of |minor |complaints.”
B) “OTC |drugs |are |considered |medications |and |should |be |reported |on |a |drug
|history.”
Test Bank For Focus on Nursing Pharmacology
| | | | | |
| 7th Edition by Amy M. Karch
| | | | |
TEST BANK |
, Test |Bank |For |Focus |on |Nursing |Pharmacology |7th |Edition |by |Amy |M. |Karch |Table
|of |Contents
Chapter |01- |Introduction |to |Drugs
|Chapter |02- |Drugs |and |the |Body
|Chapter |03- |Toxic |Effects |of |Drugs
Chapter |04- |The |Nursing |Process |in |Drug |Therapy |and |Patient |Safety
|Chapter |05- |Dosage |Calculations
Chapter |06- |Challenges |to |Effective |Drug |Therapy
|Chapter |07- |Introduction |to |Cell |Physiology
|Chapter |08- |Anti-infective |Agents
Chapter |09- |Antibiotics
|Chapter |10- |Antiviral |Agents
|Chapter |11- |Antifungal |Agents
Chapter |12- |Antiprotozoal |Agents
|Chapter |13- |Anthelmintic |Agents
|Chapter |14- |Antineoplastic |Agents
Chapter |15- |Introduction |to |the |Immune |Response |and |Inflammation
|Chapter |16- |Anti-inflammatory, |Antiarthritis, |and |Related |Agents
|Chapter |17- |Immune |Modulators
Chapter |18- |Vaccines |and |Sera
Chapter |19- |Introduction |to |Nerves |and |the |Nervous |System
|Chapter |20- |Anxiolytic |and |Hypnotic |Agents
Chapter |21- |Antidepressant |Agents
|Chapter |22- |Psychotherapeutic |Agents
|Chapter |23- |Antiseizure |Agents
|Chapter |24- |Antiparkinsonism |Agents
|Chapter |25- |Muscle |Relaxants
Chapter |26- |Narcotics, |Narcotic |Antagonists, |and |Antimigraine |Agents
|Chapter |27- |General |and |Local |Anesthetic |Agents
Chapter |28- |Neuromuscular |Junction |Blocking |Agents
|Chapter |29- |Introduction |to |the |Autonomic |Nervous |System
|Chapter |30- |Adrenergic |Agonists
Chapter |31- |Adrenergic |Antagonists
|Chapter |32- |Cholinergic |Agonists
|Chapter |33- |Anticholinergic |Agents
Chapter |34- |Introduction |to |the |Endocrine |System
|Chapter |35- |Hypothalamic |and |Pituitary |Agents
|Chapter |36- |Adrenocortical |Agents
Chapter |37- |Thyroid |and |Parathyroid |Agents
| Chapter |38- |Agents |to |Control |Blood |Glucose |Levels
|Chapter |39- |Introduction |to |the |Reproductive |System
Chapter |40- |Drugs |Affecting |the |Female |Reproductive |System
|Chapter |41- |Drugs |Affecting |the |Male |Reproductive |System
|Chapter |42- |Introduction |to |the |Cardiovascular |System
|Chapter |43- |Drugs |Affecting |Blood |Pressure
Chapter |44- |Agents |for |Treating |Heart |Failure
|Chapter |45- |Antiarrhythmic |Agents
Chapter |46- |Antianginal |Agents
|Chapter |47- |Lipid-Lowering |Agents
Chapter |48- |Drugs |Affecting |Blood |Coagulation
|Chapter |49- |Drugs |Used |to |Treat |Anemias
|Chapter |50- |Introduction |to |the |Renal |System
|Chapter |51- |Diuretic |Agents
Chapter |52- |Drugs |Affecting |the |Urinary |Tract |and |the |Bladder
|Chapter |53- |Introduction |to |the |Respiratory |System
Chapter |54- |Drugs |Acting |on |the |Upper |Respiratory |Tract
|Chapter |55- |Drugs |Acting |on |the |Lower |Respiratory |Tract
|Chapter |56- |Introduction |to |the |Gastrointestinal |System
|Chapter |57- |Drugs |Affecting |Gastrointestinal |Secretions
|Chapter |58- |Drugs |Affecting |Gastrointestinal |Motility
|Chapter |59- |Antiemetic |Agents
, Chapter |1: |Introduction |to |Drugs
Cognitive |Level: | Application
|Difficulty: | Moderate
Integrated |Process: | Nursing |process
1.A |nurse |working |in |radiology |administers |iodine |to |a |patient |who |is |having |a
|computerized |axial |tomography |(CAT) |scan. |A |nurse |working |on |an |oncology |unit
|administers |chemotherapy |to |patients |who |have |cancer. |At |the |Public |Health
|Department, |a |nurse |administers |a |measles-mumps-rubella |(MMR) |vaccine |to |a |14-
|month-old |child |as |a |routine |immunization. |Which |branch |of |pharmacology |best
|describes |the |actions |of |all |three |nurses?
A) Pharmacoeconomics
B) Pharmacotherapeutics
C) Pharmacodynamics
D) Pharmacokinetics
Ans: B
Response:
Pharmacology |is |the |study |of |the |biologic |effects |of |chemicals. |Nurses |are |involved
|with |clinical |pharmacology |or |pharmacotherapeutics, |which |is |a |branch |of
|pharmacology |that |deals |with |the |uses |of |drugs |to |treat, |prevent, |and |diagnose |disease.
|The |nurse |working |in |radiology |is |administering |a |drug |to |help |diagnose |a |disease. |The
|nurse |working |on |an |oncology |unit |is |administering |a |drug |to |help |treat |a |disease.
|Pharmacoeconomics |includes |any |costs |involved |in |drug |therapy.
Pharmacodynamics |involves |how |a |drug |affects |the |body, |and |pharmacokinetics |is
|how |the |body |acts |on |the |drug.
Cognitive |Level: |Comprehension
|Difficulty: |Easy
Integrated |Process: | Nursing |process
2.A |physician |has |ordered |intramuscular |injections |of |morphine, |a |narcotic, |every |4
|hours |as |needed |for |pain |for |a |motor |vehicle |accident |victim. |The |nurse |is |aware |that
|there |is |a |high |abuse |potential |for |this |drug; |therefore, |morphine |is |categorized |as |a:
A) Schedule |I |drug
B) Schedule |II |drug
C) Schedule |III |drug
D) Schedule |IV |drug
Ans: B
Response:
Narcotics |such |as |morphine |are |considered |schedule |II |drugs |because |of |the |high |abuse
|potential |with |severe |dependence |liability. |Schedule |I |drugs |have |high |abuse |potential
|and |no |accepted |medical |use. |Schedule |III |drugs |have |a |lesser |abuse |potential |than
|schedule |II |drugs |and |an |accepted |medical |use. |Schedule |IV |drugs |have |low |abuse
|potential |and |limited |dependence |liability.
Cognitive |Level: |Comprehension
|Difficulty: |Easy
Integrated |Process: | Communication |and |documentation
3.A |nurse |working |for |a |drug |company |is |involved |in |phase |III |drug |evaluation |studies.
|Which |of |the |following |might |the |nurse |be |responsible |for |during |this |stage |of |drug
|development?
, Chapter |1: |Introduction |to |Drugs
A) Working |with |animals |who |are |given |experimental |drugs
B) Monitoring |drug |effects |in |patients |who |are |selected |to |participate |in |a |study,
|who |have |the |disease |that |the |drug |is |meant |to |treat
C) Collecting |records |of |symptoms |that |participants |experience |while |taking |a
|drug |and |determining |whether |they |are |caused |by |the |disease |or |the |drug
D) Informing |healthy, |young |volunteer |participants |of |possible |risks |that |could
|occur |from |taking |an |experimental |drug
Ans: C
Response:
Phase |III |studies |involve |use |of |a |drug |in |a |vast |clinical |market |where |patients |are |asked
|to |record |any |symptoms |they |experience |while |taking |the |drugs. |Nurses |may |be
|responsible |for |helping |collect |and |analyze |the |information |to |be |shared |with |the | Food
|and |Drug |Administration |(FDA). |Use |of |animals |in |drug |testing |is |done |in |the
|preclinical |trials. |A |select |group |of |patients |who |are |involved |in |phase |II |studies
|participate |in |studies |where |the |participants |have |the |disease |the |drug |is |intended |to
|treat. |These |patients |are |monitored |closely |for |drug |effects. |Phase |I |studies |involve
|healthy |human |volunteers |who |are |usually |paid |for |their |participation. |Nurses |may
|observe |for |adverse |effects |and |toxicity.
Cognitive |Level: |Comprehension
|Difficulty: | Moderate
Integrated |Process: | Nursing |Process
4. Which |of |the |following |concepts |is |considered |when |generic |drugs |are |substituted |for
|brand-name |drugs?
A) Bioavailability
B) Critical |concentration
C) Distribution
D) Half-life
Ans: A
Response:
Bioavailability |is |the |portion |of |a |dose |of |a |drug |that |reaches |the |systemic |circulation
|and |is |available |to |act |on |body |cells. |Binders |used |in |a |generic |drug |may |not |be |the
|same |as |those |used |in |the |brand-name |drug. |Therefore, |the |way |the |body |breaks |down
|and |uses |the |drug |may |differ, |which |may |eliminate |a |substitution. |Critical
|concentration |is |the |amount |of |a |drug |that |is |needed |to |cause |a |therapeutic |effect.
Distribution |is |the |phase |of |pharmacokinetics |that |involves |the |movement |of |a |drug |to
|the |body's |tissues. |A |drug's |half-life |is |the |time |it |takes |for |the |amount |of |drug |to
|decrease |to |one-half |of |the |peak |level.
Cognitive |Level: | Analysis
|Difficulty: | Difficult
Integrated |Process: | Teaching/learning
5. A |nurse |is |teaching |her |patient |about |the |use |of |over-the-counter |(OTC) |drugs. |Which |of
|the |following |statements |best |informs |the |patient |about |their |safe |use?
A) “OTC |drugs |are |products |that |are |available |without |prescription |for |self-
|treatment |of |minor |complaints.”
B) “OTC |drugs |are |considered |medications |and |should |be |reported |on |a |drug
|history.”
